Journal
NEUROLOGY
Volume 66, Issue 4, Pages 587-589Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000197792.73656.c2
Keywords
-
Categories
Ask authors/readers for more resources
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl- 1- nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available